Oris
-
Bayer submits Rivaroxaban for EU marketing authorisation
Bayer has submitted an application for marketing authorization to the European Medicines Agency (EMA) for the oral anticoagulant rivaroxaban in stroke prevention in patients with atrial fibrillation (SPAF), as well as for the treatment of deep vein …
Oris | 16 February 2011
-
Amsbio Announces Cell Migration Assay
Amsbio has announced the addition of the OrisPro cell migration assay to its range of 96-well cell exclusion zone assays for performing cell migration and cell invasion experiments. The assay kit that complements the Oris cell migration assay, and…
Oris | 12 February 2010
-
Amsbio Announces Cell Migration Assay
Amsbio has announced the addition of the Oris Pro Cell Migration Assay to its range of 96-well cell exclusion zone assays for performing cell migration and cell invasion experiments. The assay kit enables researchers to save time and cost by using…
Oris | 29 January 2010
-
AstraZeneca: Diabetes Drug Receives Marketing Authorization In Europe
AstraZeneca and Bristol-Myers Squibb Company have announced that the European Commission has granted marketing authorisation for Onglyza (saxagliptin) in the 27 countries of the European Union. The drug is indicated as a once-daily 5 mg oral tabl…
Oris | 08 October 2009
-
Acoris and c-LEcta Form Strategic Partnership
Acoris Research, a wholly owned subsidiary of Hikal, and c-LEcta, a Germany-based industrial biotech company have entered into a strategic partnership to develop synthetic routes for chiral compounds. The partnership combines the expertise o…
Oris | 01 September 2009
